| Literature DB >> 31717594 |
Jong Kyou Kwon1, Do Kyung Kim2, Joo Yong Lee3, Jong Won Kim4, Kang Su Cho4.
Abstract
We attempted to visualize the periurethral stiffness of prostatic urethras using strain elastography in the midsagittal plane of transrectal ultrasonography (TRUS) and to evaluate periurethral stiffness patterns in relation to lower urinary tract symptoms (LUTS). A total of 250 men were enrolled. The stiffness patterns of the entire prostate and individual zones were evaluated using strain elastography during a TRUS examination. After excluding 69 men with inappropriate elastography images, subjects were divided according to periurethral stiffness into either group A (low periurethral stiffness, N = 80) or group B (high periurethral stiffness, N = 101). There were significant differences in patient age (p = 0.022), transitional zone volume (p = 0.001), transitional zone index (p = 0.33), total international prostate symptom score (IPSS) (p < 0.001), IPSS-voiding subscore (p < 0.001), IPSS-storage subscore (p < 0.001), and quality of life (QoL) score (p = 0.002) between groups A and B. After adjusting for relevant variables, significant differences in total IPSS, IPSS-voiding subscore, and QoL score were maintained. Men with high periurethral stiffness were associated with worse urinary symptoms than those with low periurethral stiffness, suggesting that periurethral stiffness might play an important role in the development of LUTS.Entities:
Keywords: elastography; lower urinary tract symptoms; prostatic hyperplasia
Year: 2019 PMID: 31717594 PMCID: PMC6912549 DOI: 10.3390/jcm8111929
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Measurement of prostate elastography. Elastogram-merged mapping images to the gray-scale images delineate elasticity scales with a color-coded image according to the continuous elasticity color scale (blue for the hardest area and red for the softest area). Elastography was performed on the largest transverse section (upper left) and the midsagittal plane including the entire urethral course of the prostate (upper right). Quality-scale monitoring was performed for each examination to ensure whether the elastography was performed correctly, with proper pressure and contact between the probe tip and the posterior aspect of the prostate, or not.
Figure 2Two patterns of periurethral stiffness in the sagittal planes. After repeated elastography, the images of group A showed a yellow to red signal along the urethral course from the bladder neck to verumontanum (A) and a periurethral area easily distinguishable from the prostatic tissue. Images of group B showed a green to blue signal in the proximal prostatic urethral course (B), with periurethral stiffness similar to the transitional zone.
Cases of inappropriate periurethral elastography and reasons.
| Midline Cyst or Periurethral Degenerative Cystic Nodule | 4 |
|---|---|
| Prostate calcification including periurethral calcification | 24 |
| Inappropriate quality-scale bar | 14 |
| Lacking echotexture of bladder neck and proximal urethral course in B-mode | 27 |
Figure 3The reasons for inappropriate periurethral elastography. (A) midline cyst or periurethral degenerative cystic nodule; (B) prostate calcification including periurethral calcification; (C) inappropriate quality-scale bar which failed to reach a satisfactory quality scale; (D) lacking echotexture of bladder neck and proximal urethral course in B-mode.
Comparison of prostatic parameters and urinary symptoms by periurethral stiffness before and after propensity score matching.
|
|
|
|
|
| Age (y) | 51.5 (47.0–56.0) | 54.0 (50.0–59.0) | 0.022 |
| PSA (ng/mL) | 0.949 (0.60–1.10) | 1.004 (0.60–1.20) | 0.735 |
| TPV (mL) | 25.54 ± 6.49 | 27.27 ± 7.08 | 0.092 |
| TZV (mL) | 6.76 ± 2.91 | 9.44 ± 6.42 | 0.001 |
| TZI | 0.26 ± 0.06 | 0.35 ± 0.37 | 0.033 |
| IPSS | |||
| Total | 7.38 ±4.42 | 11.12 ± 4.85 | <0.001 |
| IPSS-V | 3.18 ± 2.63 | 5.62 ± 2.98 | <0.001 |
| IPSS-S | 3.01 ± 2.17 | 4.12 ± 2.18 | <0.001 |
| Post-micturition | 1.19 ± 0.91 | 1.38 ± 1.87 | 0.074 |
| QoL | 1.81 ± 1.10 | 2.31 ± 1.01 | 0.002 |
|
|
|
|
|
| Age (y) | 52.0 (48.5–58.0) | 52.5 (48.0–57.0) | 0.660 |
| PSA (ng/mL) | 0.89 (0.60–1.10) | 0.96 (0.60–1.20) | 0.869 |
| TPV (mL) | 25.46 ± 5.76 | 24.97 ± 54.04 | 0.596 |
| TZV (mL) | 6.99 ± 2.90 | 7.01 ± 2.74 | 0.952 |
| TZI | 0.27 ± 0.62 | 0.28 ± 0.60 | 0.509 |
| IPSS | |||
| Total | 7.66 ± 4.36 | 10.51 ± 4.68 | <0.001 |
| IPSS-V | 3.24 ± 2.20 | 5.31 ± 2.73 | <0.001 |
| IPSS-S | 3.14 ± 2.17 | 3.61 ± 2.04 | 0.187 |
| Post-micturition | 1.27 ± 0.95 | 1.59 ± 1.21 | 0.089 |
| QoL | 1.84 ± 1.14 | 2.24 ± 1.04 | 0.032 |
International Prostate Symptom Score (IPSS), IPSS storage subscore (IPSS-S), IPSS voiding subscore (IPSS-V), total prostate volume (TPV), transitional zone volume (TZV), transitional zone index (TZI), prostate-specific antigen (PSA), quality of life (QoL).
Figure 4Distribution of subjects according to symptom severity using IPSS in each group before (A) and after (B) propensity score matching. In the IPSS system, the banding of symptom severity was set as 1–7 mild, 8–19 moderate, and 20–35 severe to categorize patient symptoms and to help physicians manage treatment.